The company paid cash for Praha Vaccines a.s., part of the Cyrus Poonawalla Group.
The NVX-CoV2373 vaccine was developed by American biotech company Novavax and will be tested on healthy volunteers aged 18 to 59.
"The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation", he said. "In parallel with ramping up production at Bohumil, we will continue efforts to expand antigen capacity in the USA and Asia, and increase production of Matrix-M to match antigen capacity at multiple sites globally".
But Novavax's candidate is what's referred to as a recombinant vaccine, one other kind altogether.
Novavax said, upon successful completion of Phase 1, the Phase 2 portion of the trial will be conducted in several countries, including the United States.
Most of the vaccines presently on the experimental stage are created to coach the immune system to recognise the "spike" protein that studs the coronavirus' outer floor, priming the physique to react as if it have been uncovered to the true virus. It is unclear whether either will be safe and effective. "Vaccines provide our best hope of permanently defeating this pandemic, so it is encouraging to see rapid progress being made in the development of Novavax' vaccine candidate.Our investment in Novavax allows us to focus on manufacturing in parallel with the clinical development of the vaccine, so that if the vaccine is proven to be safe and effective, we can make doses available to those who need them without delay".
Offit said the immunogenicity data was "not impressive", especially since all of the doses - even the "low" dose - were actually very high, he said.
Human coronavirus vaccine trials to begin in Australia TODAY with 130 people
The vaccine, NVX-CoV2373, is a stable, prefusion protein mode using the company's proprietary nanoparticle technology. The immune system would identify these proteins as a pathogen and label them accordingly so antibodies can block them.
Pandemic Politics Follow Trump on Visit to Michigan Ford Plant
Anthony Fauci is urging officials to be on alert. "I actually honestly - I think I look better in the mask ", the president said. Company policy maintains that visitors wear protective equipment or garments such as masks.
50 days left to get absentee ballot for July 14 runoff
The threats came one day after a federal judge in Texas ruled that state's restrictions on voting by mail unconstitutional. Michigan's secretary of state, Jocelyn Benson , tweeted back at the president stating that his allegations are false.
Novavax could make at least 100 million doses this year and 1.5 billion in 2021, he said. Moreover, if the product can beat Sanofi's flu vaccine Fluzone in the clinical trials, then it could also create greater confidence for its coronavirus vaccine.
Manufacture of the vaccine, named NVX-CoV2373, was being scaled up with 388 million dollars (£318 million) invested by Norway-based Coalition for Epidemic Preparedness Innovations since March, Dr Glenn said.
The results of the first phase of clinical trials in Melbourne and Brisbane are expected to be known in July, Novavax said.
Most of the vaccines in the pipeline aim to train the immune system to recognise the "spike" protein that studs the coronavirus' outer surface, priming the body to react if it ever encountered the real infection.
He added that should this or any other vaccine prove to be a success, it would most likely be delivered via a risk-based approach. Scientists then extracted the protein, purified it, and packaged it into virus-sized nanoparticles.
July is reportedly when the first results of the trial will be ready after time has been given to make sure those that tested have developed the required amount of antibodies to be considered immune to the virus.